Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by indaknownewfieon Aug 01, 2018 5:39pm

144 Views

Post# 28400856

RE:RE:Investor Relations - Colwell Capital

I called CEO Rob Farrell last week and he called me back immediately. He has done that each time i have reached out. He couldnt say too much but based on what he did say, i'm staying Kaly long. Would like to know what the results of FDA meeting were but maybe we are waiting for it to coincide with the AGM on the 3rd

Bullboard Posts

Catch up with companies that got a Stanley Cup Playoffs boost